top of page
Baricitinib is an oral selective inhibitor of Janus kinase 1 and 2. Previous studies have shown that baricitinib significantly reduced the concentration of anti-dsDNA antibodies and downregulated the expression of key cytokines associated with SLE pathogenesis via the JAK and signal transducer and activator of transcription (STAT; JAK–STAT) pathway.
How is Baricitenib being studied in Lupus nephritis?
The efficacy and safety of Baricitinib in patients with LN by dose 4 mg versus 2 mg versus MMF 1 gm daily dose to maintain Lupus Remission is being studied in this randomized controlled trial. The primary outcome is the urine protein creatinine ratio at 3,6 and 12 months.
Eligibility Criteria:
Aged 20-70 years
Clinical diagnosis of Lupus nephritis Disease
Lupus nephritis in remission
Enroll in this study
bottom of page